-$0.63 EPS Expected for Endologix, Inc. (NASDAQ:ELGX) This Quarter

Brokerages expect Endologix, Inc. (NASDAQ:ELGX) to report earnings of ($0.63) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Endologix’s earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.57). Endologix posted earnings of ($1.50) per share in the same quarter last year, which would indicate a positive year over year growth rate of 58%. The firm is expected to issue its next quarterly earnings results on Thursday, November 7th.

On average, analysts expect that Endologix will report full year earnings of ($2.69) per share for the current fiscal year, with EPS estimates ranging from ($3.02) to ($2.36). For the next year, analysts expect that the company will report earnings of ($2.51) per share, with EPS estimates ranging from ($4.36) to ($1.71). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Endologix.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.43. Endologix had a negative net margin of 60.32% and a negative return on equity of 154.23%. The business had revenue of $36.24 million during the quarter, compared to analyst estimates of $36.09 million.

ELGX has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Endologix from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research report on Wednesday. ValuEngine upgraded shares of Endologix from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada set a $7.00 target price on shares of Endologix and gave the stock a “hold” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $20.25.

Hedge funds have recently added to or reduced their stakes in the business. Two Sigma Investments LP lifted its position in Endologix by 49.0% during the fourth quarter. Two Sigma Investments LP now owns 804,212 shares of the medical instruments supplier’s stock valued at $576,000 after purchasing an additional 264,453 shares during the last quarter. BlackRock Inc. lifted its position in Endologix by 8.9% during the fourth quarter. BlackRock Inc. now owns 6,208,597 shares of the medical instruments supplier’s stock valued at $4,446,000 after purchasing an additional 509,493 shares during the last quarter. Northern Trust Corp lifted its position in Endologix by 15.9% during the fourth quarter. Northern Trust Corp now owns 1,215,671 shares of the medical instruments supplier’s stock valued at $871,000 after purchasing an additional 166,409 shares during the last quarter. Two Sigma Advisers LP lifted its position in Endologix by 79.5% during the fourth quarter. Two Sigma Advisers LP now owns 249,082 shares of the medical instruments supplier’s stock valued at $178,000 after purchasing an additional 110,300 shares during the last quarter. Finally, Citigroup Inc. lifted its position in Endologix by 279.2% during the fourth quarter. Citigroup Inc. now owns 51,448 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 37,882 shares during the last quarter. Institutional investors and hedge funds own 48.44% of the company’s stock.

Shares of NASDAQ:ELGX traded down $0.30 during midday trading on Thursday, reaching $6.11. 218,945 shares of the company were exchanged, compared to its average volume of 240,310. The company has a current ratio of 1.58, a quick ratio of 0.90 and a debt-to-equity ratio of 11.12. The company’s fifty day moving average is $6.81. Endologix has a one year low of $5.20 and a one year high of $26.50. The firm has a market capitalization of $113.78 million, a PE ratio of -0.85 and a beta of 0.37.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

See Also: Swap

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.